Halozyme Therapeutics (HALO) Competitors

Halozyme Therapeutics logo
$96.50 -3.77 (-3.76%)
Closing price 04:00 PM Eastern
Extended Trading
$96.49 -0.01 (-0.01%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HALO vs. ARGX, NTRA, RVMD, BIIB, and GMAB

Should you buy Halozyme Therapeutics stock or one of its competitors? Halozyme Therapeutics's main competitors and comparable companies include argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Halozyme Therapeutics compare to argenex?

argenex (NASDAQ:ARGX) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

60.3% of argenex shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

argenex has a net margin of 31.66% compared to Halozyme Therapeutics' net margin of 26.93%. Halozyme Therapeutics' return on equity of 751.81% beat argenex's return on equity.

Company Net Margins Return on Equity Return on Assets
argenex31.66% 47.70% 40.12%
Halozyme Therapeutics 26.93%751.81%23.84%

argenex has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenex$4.25B14.21$1.29B$28.6633.50
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51

argenex has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

In the previous week, argenex had 5 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 17 mentions for argenex and 12 mentions for Halozyme Therapeutics. argenex's average media sentiment score of 0.52 beat Halozyme Therapeutics' score of 0.13 indicating that argenex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
argenex
6 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

argenex presently has a consensus target price of $1,155.24, suggesting a potential upside of 20.33%. Halozyme Therapeutics has a consensus target price of $108.18, suggesting a potential upside of 7.89%. Given argenex's stronger consensus rating and higher possible upside, research analysts plainly believe argenex is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenex
0 Sell rating(s)
6 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.82
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46

Summary

argenex beats Halozyme Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Natera?

Natera (NASDAQ:NTRA) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

99.9% of Natera shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 26.93% compared to Natera's net margin of -5.66%. Halozyme Therapeutics' return on equity of 751.81% beat Natera's return on equity.

Company Net Margins Return on Equity Return on Assets
Natera-5.66% -8.61% -5.93%
Halozyme Therapeutics 26.93%751.81%23.84%

Natera currently has a consensus target price of $394.31, indicating a potential upside of 36.69%. Halozyme Therapeutics has a consensus target price of $108.18, indicating a potential upside of 12.11%. Given Natera's stronger consensus rating and higher possible upside, research analysts plainly believe Natera is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46

Natera has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Halozyme Therapeutics has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$2.31B18.14-$208.16M-$1.14N/A
Halozyme Therapeutics$1.40B7.88$316.89M$3.9324.55

In the previous week, Natera and Natera both had 15 articles in the media. Natera's average media sentiment score of 0.37 beat Halozyme Therapeutics' score of 0.03 indicating that Natera is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Natera
4 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Halozyme Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Natera beats Halozyme Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Revolution Medicines?

Halozyme Therapeutics (NASDAQ:HALO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Halozyme Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51
Revolution Medicines$197.56M188.63-$1.13B-$9.11N/A

Halozyme Therapeutics presently has a consensus price target of $108.18, suggesting a potential upside of 7.89%. Revolution Medicines has a consensus price target of $262.75, suggesting a potential upside of 52.50%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.92

In the previous week, Revolution Medicines had 9 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 21 mentions for Revolution Medicines and 12 mentions for Halozyme Therapeutics. Revolution Medicines' average media sentiment score of 0.94 beat Halozyme Therapeutics' score of 0.13 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Revolution Medicines
7 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Halozyme Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Halozyme Therapeutics has a net margin of 26.93% compared to Revolution Medicines' net margin of 0.00%. Halozyme Therapeutics' return on equity of 751.81% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics26.93% 751.81% 23.84%
Revolution Medicines N/A -84.51%-51.97%

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Revolution Medicines beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Biogen?

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Halozyme Therapeutics has a net margin of 26.93% compared to Biogen's net margin of 3.37%. Halozyme Therapeutics' return on equity of 751.81% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics26.93% 751.81% 23.84%
Biogen 3.37%9.38%5.69%

Biogen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51
Biogen$9.89B3.79$1.29B$2.34108.29

Halozyme Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, Biogen has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Biogen had 12 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 24 mentions for Biogen and 12 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.33 beat Halozyme Therapeutics' score of 0.13 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biogen
17 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Halozyme Therapeutics currently has a consensus target price of $108.18, indicating a potential upside of 7.89%. Biogen has a consensus target price of $254.41, indicating a potential upside of 0.40%. Given Halozyme Therapeutics' higher probable upside, research analysts plainly believe Halozyme Therapeutics is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67

Summary

Halozyme Therapeutics beats Biogen on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Genmab A/S?

Halozyme Therapeutics (NASDAQ:HALO) and Genmab A/S (NASDAQ:GMAB) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51
Genmab A/S$3.72B8.62$963M$1.1743.91

Halozyme Therapeutics has a net margin of 26.93% compared to Genmab A/S's net margin of 16.97%. Halozyme Therapeutics' return on equity of 751.81% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics26.93% 751.81% 23.84%
Genmab A/S 16.97%13.67%6.42%

Halozyme Therapeutics presently has a consensus target price of $108.18, suggesting a potential upside of 7.89%. Genmab A/S has a consensus target price of $53.50, suggesting a potential upside of 4.15%. Given Halozyme Therapeutics' higher possible upside, equities research analysts plainly believe Halozyme Therapeutics is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00

Halozyme Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

In the previous week, Genmab A/S had 7 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 19 mentions for Genmab A/S and 12 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.13 beat Genmab A/S's score of -0.15 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Genmab A/S
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Halozyme Therapeutics beats Genmab A/S on 9 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HALO vs. The Competition

MetricHalozyme TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$11.48B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio18.0726.5532.9127.39
Price / Sales7.8816.028.595.74
Price / Cash21.1026.3721.9322.50
Price / Book-201.044.074.403.70
Net Income$316.89M-$22.86M$3.52B$392.17M
7 Day Performance-6.24%-7.26%-5.34%-4.53%
1 Month Performance-20.80%-4.96%-3.61%-5.86%
1 Year Performance37.80%-2.87%0.01%-7.78%

Halozyme Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
Halozyme Therapeutics
4.26 of 5 stars
$96.50
-3.8%
$108.18
+12.1%
+43.2%$11.48B$1.40B18.07423
ARGX
argenex
4.5682 of 5 stars
$962.27
+3.8%
$1,158.76
+20.4%
+5.7%$58.57B$4.25B33.581,863
NTRA
Natera
3.4066 of 5 stars
$320.39
+3.1%
$394.31
+23.1%
+56.2%$56.36B$2.31BN/A6,140
RVMD
Revolution Medicines
3.1999 of 5 stars
$200.15
+4.1%
$263.15
+31.5%
+154.3%$42.80B$11.58MN/A883
BIIB
Biogen
2.9954 of 5 stars
$254.87
+2.6%
$254.41
-0.2%
+51.2%$37.61B$9.89B108.927,500

Related Companies and Tools


This page (NASDAQ:HALO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners